![](/img/cover-not-exists.png)
1092PDAN UPDATE ON OVERALL SURVIVAL (OS) AND FOLLOW-ON THERAPIES IN BREAK-3, A PHASE III, RANDOMIZED TRIAL: DABRAFENIB (D) VS. DACARBAZINE (DTIC) IN PATIENTS (PTS) WITH BRAF V600E MUTATION-POSITIVE METASTATIC MELANOMA (MM)
Hauschild, A., Grobb, J., Demidov, L., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C., Miller, W., Martin-Algarra, S., Karaszewska, B., Mauch, C., Chiarion Sileni, V., Aktan, G., HaneVolume:
25
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdu344.8
Date:
September, 2014
File:
PDF, 70 KB
2014